A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis.

about

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis.

Item

http://www.wikidata.org/entity/Q36329737

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

A High-throughput Compatible A ...... ed Mycobacterium tuberculosis.

@ast

A High-throughput Compatible A ...... ed Mycobacterium tuberculosis.

@en

type

Item

label

A High-throughput Compatible A ...... ed Mycobacterium tuberculosis.

@ast

A High-throughput Compatible A ...... ed Mycobacterium tuberculosis.

@en

prefLabel

A High-throughput Compatible A ...... ed Mycobacterium tuberculosis.

@ast

A High-throughput Compatible A ...... ed Mycobacterium tuberculosis.

@en

P1476

A High-throughput Compatible A ...... ed Mycobacterium tuberculosis.

@en

P2093

Kaitlyn Schaaf

http://www.w3.org/2001/XMLSchema#string

Olaf Kutsch

http://www.w3.org/2001/XMLSchema#string

Virginia Hayley

http://www.w3.org/2001/XMLSchema#string

P2860

Understanding anti-tuberculosis drug efficacy: rethinking bacterial populations and how we model them

Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium

High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors

Looking back to the future: predicting in vivo efficacy of small molecules versus Mycobacterium tuberculosis

The role of the granuloma in expansion and dissemination of early tuberculous infection.

Specialized transduction designed for precise high-throughput unmarked deletions in Mycobacterium tuberculosis.

Assessment of immunity to mycobacterial infection with luciferase reporter constructs.

Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.

The challenge of new drug discovery for tuberculosis.

Can the duration of tuberculosis treatment be shortened with higher dosages of rifampicin?

P31

scholarly article

P356

10.3791/55453

http://www.w3.org/2001/XMLSchema#string

P433

121

http://www.w3.org/2001/XMLSchema#string

P50

Jim Sun

Samuel R Smith

P577

2017-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28362407

http://www.w3.org/2001/XMLSchema#string

P921

Mycobacterium tuberculosis

macrophage

P932

5409311

http://www.w3.org/2001/XMLSchema#string